MONMOUTH JUNCTION, N.J., March 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM 2022) Congress in Brussels, Belgium being held March 22-25, 2022. CytoSorbents is a platinum sponsor of the Congress and will have a strong contingent of sales, marketing, and medical affairs personnel in attendance.
Importantly, new data from the CytoSorb Therapy in COVID-19 (CTC) Multicenter Registry will be presented on Tuesday, March 22, 2022, in an abstract titled: Relationship of Lung Oxygenation to Timing of Hemoadsorption Therapy Initiation in COVID-19 Patients Requiring Extracorporeal Mechanical Oxygenation (ECMO): An Observational Analysis from the CytoSorb Therapy in COVID-19 (CTC) Registry. This new analysis on 56 critically ill COVID-19 patients on life support with ECMO and treated with CytoSorb under FDA Emergency Use Authorization (EUA) provides additional insights into the mechanisms underlying the high survival rates published in the journal, Frontiers in Medicine, last year.
The CTC Registry has now completed enrollment after reaching the milestone of 100 critically ill COVID-19 patients enrolled with refractory respiratory failure on both CytoSorb and ECMO. Top-line results from these 100 patients confirm the high survival rates reported previously on the first 52 patients, and are expected to be presented and published in detail later this year.
CytoSorbents will also hold an onsite educational symposium and virtual webinar entitled Hemoadsorption with CytoSorb as Part of an Individualized Therapy in Critically Ill Patients on Thursday, March 24, 2022, from 12:30-1:30 PM CET in the Copper Hall.
Prof. Manu Malbrain (Leuven, Belgium) and Dr. Yatin Mehta (Chairman, Institute of Critical Care and Anesthesiology, India)
Dr. Axel Nierhaus (University Medical Center Hamburg-Eppendorf, Germany)
How to Balance Sepsis Campaign Guidelines and the Need for Patient Tailored Care?
Dr. Gabriella Bottari (Bambino Gesù Children’s Hospital, Rome, Italy)
Use of CytoSorb in Different Pediatric Indications – an Overview
Prof. Dietmar Fries (Medical University Innsbruck, Austria)
Hemoadsorption in Severe Rhabdomyolysis and for Prevention of DOAC Associated Bleeding Complications
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to be able to sponsor and actively participate in next week’s ISICEM scientific meeting, one of the first major in-person medical conferences for us this year. It is a sign that business activities are starting to slowly return to normal. We are excited to be meeting with key opinion leaders, customers, and partners from the global medical community to communicate our progress, and to share our latest experiences and clinical data with them, using CytoSorb in a diverse set of critical care applications. We encourage attendees to visit our exhibit booth and attend our educational symposium on March 24, 2022.”
About U.S. FDA Emergency Use Authorization
CytoSorb received U.S. FDA EUA in April 2020 for use in adult, critically ill COVID-19 patients with confirmed or imminent respiratory failure and is indicated to reduce cytokines in these patients. It has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the CytoSorb device under Section 564(b)(l) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
About the CTC Registry
CytoSorbents launched the multicenter CTC Registry following the issuance of U.S. FDA Emergency Use Authorization for CytoSorb therapy in adult, critically ill COVID-19 patients with confirmed or imminent respiratory failure in April 2020. The registry was designed to capture high fidelity data on device utilization patterns and associated clinical outcomes from participating U.S. centers with a pre-specified primary endpoint of ICU mortality. The CTC Registry has now completed enrollment after reaching the milestone of 100 patients enrolled. For more information on the CTC Registry, please view study number NCT04391920 on www.clinicaltrials.gov.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31, 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb-ATR™ Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR–D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
U.S. Public Relations Contact:
Rubenstein Public Relations
SOURCE CytoSorbents Corporation